Resources

Find information and resources to support your desmoid tumor patients, from diagnosis through treatment with OGSIVEO.

Important Considerations

This publication includes both data consistent with the OGSIVEO Prescribing Information and data that are not included in the Prescribing Information
Data not found within the Prescribing Information should be interpreted with caution and could represent chance findings
For complete information regarding the use of OGSIVEO, please see the full Prescribing Information

Analysis Limitations

The long-term data are based on a post-hoc analysis in patients initially randomized to OGSIVEO in the DeFi study
In an open-label extension, there is a potential for enrichment of the long-term data in the remaining patient populations since patients who are unable to tolerate or do not respond to the drug often drop out
Extension data are as observed and should be considered descriptive in nature
No conclusions of safety or efficacy should be made based on these results
These data are not included in the OGSIVEO Prescribing Information

Continue Download

Use this filter to quickly find resources relevant to you.

Reset

Side Effect Management Resource Guide

Review practical strategies for helping patients stay on track with their therapy, including recommended dose modifications to help manage certain side effects.

Download

How to Order/Rx Guide

Discover how to prescribe OGSIVEO for your adult patients with progressing desmoid tumors who require systemic treatment.

Download

DeFi Study Publication

Review the results of the pivotal DeFi study published in The New England Journal of Medicine. This publication contains data and analyses that are not included in the OGSIVEO Prescribing Information. Please see FULL PRESCRIBING INFORMATION on this website.

Download

Long-Term Data From the DeFi Trial

Review up to four years of long-term data from the DeFi trial in the Journal of Clinical Oncology. This publication contains data and analyses that are not included in the OGSIVEO Prescribing Information. Please see FULL PRESCRIBING INFORMATION on this website.

Download

OGSIVEO Overview for Healthcare Professionals

Review a summary of key information about OGSIVEO, including clinical data, guideline recommendations, and information about adverse events.

Download

ICD-10-CM Codes for Desmoid Tumors

Location-specific ICD-10-CM codes for desmoid tumors went into effect on October 1, 2023. The codes can help you document location-specific desmoid tumor diagnoses in your patients.

Download

Patient Brochure

This brochure provides an overview of OGSIVEO for patients considering or starting treatment. It includes safety information, dosing instructions, educational content on desmoid tumors, and more.

English

Spanish

Patient Treatment Tracker

Provide your patients with this tool to help them track symptoms and potential side effects throughout their treatment.  

Download

SpringWorks CareConnections® HCP Brochure

SpringWorks CareConnections provides personalized support services and resources to help your patients start and stay on track with OGSIVEO.

Download

SpringWorks CareConnections Enrollment Form

Complete this form to get your patients enrolled in SpringWorks CareConnections. 

English

Spanish

Patient Profiles

Explore hypothetical patient profiles to learn about examples of progressing desmoid tumors and when treatment with OGSIVEO may be appropriate.

See Patient Profiles

OGSIVEO Digital Companion

Available through the free Medisafe app, patients can set up personalized medication reminders and alerts, and receive other helpful tips throughout their treatment journey.

Learn More

Advocacy Groups

The following advocacy organizations can provide additional support and information for your patients with desmoid tumors

The organizations listed are independent of SpringWorks Therapeutics. SpringWorks Therapeutics is providing these links to help patients find more information about desmoid tumors, but inclusion on this list does not represent an endorsement or a recommendation from SpringWorks Therapeutics for any group or organization. Logos are used with permission.

Patient Profiles

Indication

OGSIVEO is indicated for adult patients with progressing desmoid tumors who require systemic treatment.

Important Safety Information

Warnings And Precautions

Diarrhea: Diarrhea, sometimes severe, can occur in patients treated with OGSIVEO. Diarrhea occurred in 84% of patients treated with OGSIVEO, and included Grade 3 events in 16% of patients. Median time to first diarrhea event was 9 days (range: 2 to 434 days). Monitor patients and manage using antidiarrheal medications. Modify dose as recommended.

Ovarian Toxicity: Female reproductive function and fertility may be impaired in patients treated with OGSIVEO. Impact on fertility may depend on factors like duration of therapy and state of gonadal function at time of treatment. Long-term effects of OGSIVEO on fertility have not been established. Advise patients on the potential risks for ovarian toxicity before initiating treatment. Monitor patients for changes in menstrual cycle regularity or the development of symptoms of estrogen deficiency, including hot flashes, night sweats, and vaginal dryness.

Hepatotoxicity: ALT or AST elevations occurred in 30% and 33% of patients, respectively. Grade 3 ALT or AST elevations (>5 x ULN) occurred in 6% and 2.9% of patients. Monitor liver function tests regularly and modify dose as recommended.

Non-Melanoma Skin Cancers: New cutaneous squamous cell carcinoma and basal cell carcinoma occurred in 2.9% and 1.4% of patients, respectively. Perform dermatologic evaluations prior to initiation of OGSIVEO and routinely during treatment.

Electrolyte Abnormalities: Decreased phosphate (65%) and potassium (22%) occurred in OGSIVEO-treated patients. Phosphate <2 mg/dL occurred in 20% of patients. Grade 3 decreased potassium occurred in 1.4% of patients. Monitor phosphate and potassium levels regularly and supplement as necessary. Modify dose as recommended.

Embryo-Fetal Toxicity: OGSIVEO can cause fetal harm when administered to pregnant women. Oral administration of nirogacestat to pregnant rats during the period of organogenesis resulted in embryo-fetal toxicity and death at maternal exposures below human exposure at the recommended dose of 150 mg twice daily. Advise pregnant women of the potential risk to a fetus. Advise females and males of reproductive potential to use effective contraception during treatment with OGSIVEO and for 1 week after the last dose.

Adverse Reactions

The most common (≥15%) adverse reactions were diarrhea (84%), ovarian toxicity (75% in the 36 females of reproductive potential), rash (68%), nausea (54%), fatigue (54%), stomatitis (39%), headache (30%), abdominal pain (22%), cough (20%), alopecia (19%), upper respiratory tract infection (17%), and dyspnea (16%).

Serious adverse reactions occurred in 20% of patients who received OGSIVEO. Serious adverse reactions occurring in ≥2% of patients were ovarian toxicity (4%).

The most common laboratory abnormalities (≥15%) were decreased phosphate, increased urine glucose, increased urine protein, increased AST, increased ALT, and decreased potassium.

Drug Interactions

CYP3A Inhibitors and Inducers: Avoid concomitant use with strong or moderate CYP3A inhibitors (including grapefruit products, Seville oranges, and starfruit) and strong or moderate CYP3A inducers.

Gastric Acid Reducing Agents: Avoid concomitant use with proton pump inhibitors and H2 blockers. If concomitant use cannot be avoided, OGSIVEO can be staggered with antacids (e.g., administer OGSIVEO 2 hours before or 2 hours after antacid use).

Consult the full Prescribing Information prior to and during treatment for important drug interactions.

Use in Specific Populations

Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with OGSIVEO and for 1 week after the last dose.

OGSIVEO may reduce the effectiveness of hormonal contraceptives. Addition of a barrier method is recommended for females using hormonal contraceptives.

Please click here for full Prescribing Information.

Indication

OGSIVEO is indicated for adult patients with progressing desmoid tumors who require systemic treatment.

Please click here for full Prescribing Information.

Important Safety Information

Indication

OGSIVEO is indicated for adult patients with progressing desmoid tumors who require systemic treatment.

Important Safety Information

Warnings And Precautions

Adverse Reactions

Serious adverse reactions occurred in 20% of patients who received OGSIVEO. Serious adverse reactions occurring in ≥2% of patients were ovarian toxicity (4%).

The most common laboratory abnormalities (≥15%) were decreased phosphate, increased urine glucose, increased urine protein, increased AST, increased ALT, and decreased potassium.

Drug Interactions

Consult the full Prescribing Information prior to and during treatment for important drug interactions.

Use in Specific Populations

Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with OGSIVEO and for 1 week after the last dose.

OGSIVEO may reduce the effectiveness of hormonal contraceptives. Addition of a barrier method is recommended for females using hormonal contraceptives.

Please click here for full Prescribing Information.

Indication

OGSIVEO is indicated for adult patients with progressing desmoid tumors who require systemic treatment.

Please click here for full Prescribing Information.

Resources

Important Considerations

Analysis Limitations

Side Effect Management Resource Guide

How to Order/Rx Guide

DeFi Study Publication

Long-Term Data From the DeFi Trial

OGSIVEO Overview for Healthcare Professionals

Sign Up for Information About OGSIVEO

ICD-10-CM Codes for Desmoid Tumors

Patient Brochure

Patient Treatment Tracker

SpringWorks CareConnections® HCP Brochure

SpringWorks CareConnections Enrollment Form

Patient Profiles

OGSIVEO Digital Companion

Advocacy Groups

Important Safety Information